Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Graphic promoting a publication on discovering potent JAK1/2 inhibitors that block IL‑13 signaling, with a ‘View Publication’ button and Pharmaron branding

Capabilities

Knowledge Center
Laboratory Chemistry
Connect with a Scientific Expert

Authors: Mark Zak, Emily J. Hanan, Patrick Lupardus, David G. Brown, Colin Robinson, Michael Siu, Joseph P. Lyssikatos, F. Anthony Romero, Guiling Zhao, Terry Kellar, Rohan Mendonca, Nicholas C. Ray, Simon C. Goodacre, Peter H. Crackett, Neville McLean, Christopher A. Hurley, Po-Wai Yuen, Yun-Xing Cheng, Xiongcai Liu, Marya Liimatta, Pawan Bir Kohli, Jim Nonomiya, Gary Salmon, Gerry Buckley, Julia Lloyd, Paul Gibbons, Nico Ghilardi, Jane R Kenny, Adam Johnson

Bioorg Med Chem Lett. 2019 Jun 15;29(12):1522-1531

DOI: 10.1016/j.bmcl.2019.04.008

Access the publication at:https://pubmed.ncbi.nlm.nih.gov/30981576/